Faeth Therapeutics, Inc. (FTH) News
Follow Faeth Therapeutics, Inc. (FTH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Faeth Reports Positive Preliminary Phase 2 Trial Results
Faeth said preliminary Phase 2 results for PIKTOR in an endometrial cancer trial were positive.
EQUITY | Nov 09, 2026, 12:23 PM UTC
M
Faeth Therapeutics Reports Third-Quarter Net Loss of $20.4 Million
Faeth reported a $20.4 million net loss for the third quarter of 2026, compared with a $4.6 million loss a year earlier. Basic and diluted loss per share narrowed to $0.79 from $3.62.
EQUITY | Nov 03, 2026, 01:11 PM UTC
M
Faeth Therapeutics Reports Third-Quarter Loss per Share
EQUITY | Nov 03, 2026, 12:33 PM UTC
M
Faeth Therapeutics Reports Third-Quarter Loss of $20.4 Million
EQUITY | Nov 03, 2026, 12:33 PM UTC
M
Faeth Therapeutics Reports 4Q Loss of $20.4 Million
EARNINGS | Nov 03, 2026, 12:30 PM UTC
M
Faeth Therapeutics Reports Third-Quarter 2026 Results and Operational Updates
Faeth Therapeutics announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.
EQUITY | Nov 03, 2026, 12:30 PM UTC
L
FTH: Oral multi-node inhibition demonstrates strong early efficacy and tolerability, with pivotal data expected soon
Multi-node inhibition targeting PI3K/AKT/mTOR shows promising efficacy and tolerability in early trials, with oral administration offering key advantages. Upcoming phase II data in endometrial cancer and ongoing breast c
EQUITY | Sep 10, 2026, 02:53 PM UTC
L
Faeth Therapeutics initiated at Buy by TD Cowen
Faeth Therapeutics was initiated at a Buy rating by TD Cowen.
EQUITY | Sep 09, 2026, 02:40 PM UTC
L
Faeth Therapeutics to host virtual KOL event on Oct. 6, 2026
Faeth Therapeutics said it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET, focused on multi-nodal inhibition for endometrial cancer treatment.
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Faeth Therapeutics to participate in September investor conferences
Faeth Therapeutics (FTH) says management will participate in upcoming September investor conferences, with live webcasts available for Cantor and Morgan Stanley events.
EQUITY | Sep 01, 2026, 11:30 AM UTC
L
Faeth Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4)
Faeth Therapeutics announced inducement grants under Nasdaq listing rule 5635(c)(4).
EQUITY | Aug 28, 2026, 11:30 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
FTH int Outperform @ Oppenheimer pt $60
FTH int Outperform @ Oppenheimer pt $60
EQUITY | Jul 28, 2026, 09:45 AM UTC
L
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted six new employees options to purc
EQUITY | Jul 03, 2026, 08:00 PM UTC
M
HOOD: BTIG Initiates
BTIG analyst initiates coverage on Robinhood Markets with a Buy rating
EQUITY | Jun 26, 2026, 12:58 PM UTC
M
BDC: BUY @ Citi
Citi initiates BDC with a BUY rating, among other top initiations
EQUITY | Jun 26, 2026, 11:17 AM UTC
M
FTH: Baird Initiates
Baird initiates coverage on Faeth Therapeutics with Outperform rating and $57 price target
EQUITY | Jun 26, 2026, 11:06 AM UTC
M
CRDO: Credo Initiated
Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis
EQUITY | Jun 22, 2026, 12:39 PM UTC
M
FTH: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on Faeth Therapeutics with a buy rating and a price target of $60
EQUITY | Jun 22, 2026, 11:05 AM UTC